PWMG
VKTX icon

Pinnacle Wealth Management Group’s Viking Therapeutics VKTX Stock Holding History

Pinnacle Wealth Management Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375K Buy
9,610
+45
+0.5% +$1.45K 0.17% 92
2026
Q1 		$311K Hold
9,565
– – 0.15% 97
2025
Q4 		$336K Hold
9,565
– – 0.17% 89
2025
Q3 		$251K Buy
+9,565
New +$285K 0.13% 113

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Pinnacle Wealth Management Group's VKTX Position: Q2 2026 in Review

Pinnacle Wealth Management Group increased its Viking Therapeutics (VKTX) stake by 0.47% in Q2 2026, buying an estimated $1.45K and bringing the position to 9,610 shares worth $375K. The position accounts for 0.17% of the portfolio, ranked #92.

Pinnacle Wealth Management Group first reported a position in VKTX in Q3 2025 and has held it in 4 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Pinnacle Wealth Management Group held 9,610 shares of Viking Therapeutics worth $375K as of Q2 2026.
  • Pinnacle Wealth Management Group bought 45 Viking Therapeutics shares in Q2 2026, an estimated $1.45K.
  • Viking Therapeutics made up 0.17% of Pinnacle Wealth Management Group's portfolio in Q2 2026, its #92 holding.
  • Pinnacle Wealth Management Group first reported a position in Viking Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Pinnacle Wealth Management Group's 13F filing for Q2 2026, filed 15 Jul 2026.